Evidence map›Paper›PMID 42736262›Full record

ReviewSignal transduction and targeted therapy2026

The histone deacetylase family in health and disease.

Ri Wen, Yu-Hang Yang, Tao Zhang, Sen-Yu Zhang, Xin-Ru Yang, Li-Ying Zhang, Peng-Hui Hao, Yue Zheng, Ni Yang, Tie-Ning Zhang

Abstract readReview
In one paragraph

Review in Signal transduction and targeted therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ri Wen *Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China.
Yu-Hang Yang *Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China.
Tao Zhang *Department of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China.
Sen-Yu ZhangDepartment of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China.
Xin-Ru YangDepartment of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China.
Li-Ying ZhangDepartment of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China.
Peng-Hui HaoDepartment of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China.
Yue ZhengDepartment of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China.
Ni YangDepartment of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China. yangni616@hotmail.com.
Tie-Ning ZhangDepartment of Pediatrics, Shengjing Hospital of China Medical University, Shenyang, China. cmuztn@sj-hospital.org.ORCID http://orcid.org/0000-0003-4954-5370

Funding

Natural Science Foundation of Liaoning Province (Liaoning Provincial Natural Science Foundation) 2024-BSLH-329Natural Science Foundation of Liaoning Province (Liaoning Provincial Natural Science Foundation) 2024-MS-067Natural Science Foundation of Liaoning Province (Liaoning Provincial Natural Science Foundation) 2024-MS-077
6 · The paper itself

Abstract

Zinc-dependent classical histone deacetylases, including Classes I, II, and IV, are ubiquitously present in mammals and play vital roles in numerous biological processes. To date, eleven histone deacetylase members have been identified, namely, histone deacetylase 1 through histone deacetylase 11. A growing body of evidence underscores the crucial roles of these histone deacetylase members in both physiological and pathological conditions. Notably, these histone deacetylase members are involved in various cellular processes, including inflammation, metabolism, apoptosis, and oxidative stress. Consequently, histone deacetylases have emerged as promising therapeutic targets for a range of pathological conditions, including tumors, cardiovascular diseases, and neurological disorders. Moreover, the development of histone deacetylase modulators, which can regulate their activity, has shown significant therapeutic potential across various conditions. Several histone deacetylase inhibitors have been approved by the U.S. Food and Drug Administration for the treatment of multiple tumors and Duchenne muscular dystrophy, while many others are being developed for oncology and other therapeutic applications. In this review, we introduce the research history and structural characteristics of histone deacetylases. We then summarize the molecular mechanisms and biological functions of the eleven histone deacetylase family members. Moreover, we elucidate the critical regulatory roles of histone deacetylases in various human diseases. Furthermore, we provide an overview of histone deacetylase modulators, their current clinical applications, and potential benefits, offering insight into the regulation of histone deacetylases for the treatment of related diseases.

Indexed as

Cardiovascular DiseasesHistone Deacetylase InhibitorsHistone DeacetylasesNeoplasmsNervous System DiseasesAnimalsApoptosisHumansOxidative StressHistone Deacetylase InhibitorsHistone Deacetylases

Identifiers

PMID42736262
PMCPMC13575227

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.